Table 1.
Ongoing clinical trials of molecularly targeted drugs in esophageal cancer.
| NCT No. | Drug | Target | Disease | Phase |
|---|---|---|---|---|
| NCT02465060 | Crizotinib | c-MET | Esophageal cancer | Ⅱ |
| NCT04491942 | Elimusertib + chemotherapy | ATR | Esophageal cancer | Ⅰ |
| NCT04460937 | Adavosertib + radiotherapy | WEE1 | Esophageal cancer | Ⅰ |
| NCT04171700 | Rucaparib | PARP | Esophageal cancer | Ⅱ |
| NCT01366144 | Veliparib + chemotherapy | PARP | Esophageal cancer | Ⅰ |
| NCT03233724 | Decitabine | DNMT | Esophageal cancer | Ⅰ/Ⅱ |
| NCT03544736 | Nivolumab + radiotherapy | PD-1 | Esophageal cancer | Ⅰ/Ⅱ |
| NCT03691090 | Camrelizumab + chemotherapy | PD-1 | Esophageal cancer | Ⅲ |
| NCT02639065 | Durvalumab | PD-L1 | Esophageal cancer | Ⅱ |
| NCT03940976 | Afatinib | EGFR | ESCC | Ⅱ |
| NCT02409186 | Nimotuzumab + chemoradiotherapy | EGFR | ESCC | Ⅲ |
| NCT03770988 | Poziotinib | EGFR | ESCC | Ⅱ |
| NCT03126708 | Cetuximab | EGFR | ESCC | Ⅱ |
| NCT02699606 | Erdafitinib | FGFR | Esophageal cancer | Ⅱ |
| NCT01795768 | AZD4547 | FGFR | Esophageal cancer | Ⅱ |
| NCT03292250 | Alpelisib | PI3Kα | ESCC | Ⅱ |
| NCT03544905 | CYH33 | PI3Kα | ESCC | Ⅰ |
| NCT01351103 | LGK974 | Wnt | ESCC | Ⅰ |
| NCT04430738 | Tucatinib | HER2 | EAC | Ⅰ/Ⅱ |
| NCT03783936 | Trastuzumab + avelumab | HER2 | EAC | Ⅱ |
| NCT04499924 | Tucatinib | HER2 | EAC | Ⅱ/Ⅲ |
| NCT01359397 | Bevacizumab + chemotherapy | VEGFR | EAC | Ⅱ |
| NCT02898077 | Apatinib + chemotherapy | VEGFR | Esophageal cancer | Ⅱ |